Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Greenbrook logo — Greenbrook is a leading provider of TMS therapy & Spravato®...

Greenbrook

Greenbrook is a leading provider of TMS therapy & Spravato® nasal esketamine treatment for depression & OCD.

Founded 2011 United States Mclean, United States 357 employees Post-IPO Equity Total: $24.00M Health Care

General Information

Company Name Greenbrook
Founded Year 2011
Location United States Mclean, United States
Employees 357
Industries Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Greenbrook. To contact Greenbrook, visit greenbrookproviders.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Greenbrook compare?

A PDF of Greenbrook and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Greenbrook soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Greenbrook

Greenbrook is a healthcare startup dedicated to providing advanced and compassionate mental health care solutions. The company operates healthcare centers that offer repetitive transcranial magnetic stimulation therapy (TMS) to address major depressive disorder (MDD) and other neurological conditions. Through electromagnetic stimulation targeting specific mood-regulating brain areas, Greenbrook aims to rejuvenate lives. Additionally, the company offers Spravato to address depressive symptoms in adults with MDD, especially those experiencing suicidal thoughts or treatment-resistant depression. Greenbrook's comprehensive treatment experience includes managing insurance coverage and logistics while keeping patients informed and engaged throughout the process. Founded in 2011, Greenbrook received a significant Post-IPO Equity investment of $1.20M on 22 February 2024. This infusion of capital is indicative of investor confidence in the company's mission and potential for growth in the mental healthcare sector. While the details of the investor(s) behind this investment are currently unavailable, this funding is expected to propel Greenbrook's innovative solutions and patient-centered approach to mental health care to greater heights.

Business keywords: TMS Therapy, Mental Health Care, Depression Treatment, Neurological Disorders, Transcranial Magnetic Stimulation, Spravato Treatment, Healthcare Centers, Insurance Coverage, Suicidal Thoughts, Treatment-Resistant Depression, Obsessive Compulsive Disorder, Esketamine Treatment, Outpatient Treatment, Compassionate Care, Patient Engagement

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $1.20M -
22 Feb 2024
Post IPO Debt $2.54M 1
Madryn Asset Management
Madryn Asset Management
19 Jan 2024
Post IPO Debt $5.30M 1
Madryn Asset Management
Madryn Asset Management
28 Dec 2023
Post IPO Debt $4.02M 1
Madryn Asset Management
Madryn Asset Management
15 Dec 2023
Post IPO Debt $2.50M 1
Madryn Asset Management
Madryn Asset Management
05 Dec 2023
Post IPO Debt $2.05M 1
Madryn Asset Management
Madryn Asset Management
02 Nov 2023
Post IPO Debt $1.50M 1
Madryn Asset Management
Madryn Asset Management
13 Oct 2023
Post IPO Debt $1.90M 2
Madryn Asset Management
Madryn Asset Management, Greybrook Realty Partners
03 Oct 2023
Post IPO Debt $3.00M 1
Greybrook Realty Partners
01 Aug 2023

Greenbrook Alternatives & Competitors

View All Alternatives
Greenbrook vs
Neuronetics, Inc.
Neuronetics, Inc. United States

Non-drug, safe, effective treatment for depression and other mental health conditions.

Post-IPO Debt
220 employees
Biotechnology, Health Care
Compare Greenbrook vs Neuronetics, Inc.
Greenbrook vs
Neuro Wellness Spa
Neuro Wellness Spa United States

Mental health care, reimagined. In-network Psychiatry, TMS & Spravato. Online & in-person appointmen...

53 employees
Health Care, Health and Wellness
Compare Greenbrook vs Neuro Wellness Spa
Greenbrook vs
Modalis TMS
Modalis TMS Australia

WA's trusted name in using Transcranial Magnetic Stimulation (TMS) to treat depression & more | Pert...

15 employees
Health Care, Health and Wellness
Also compare with: Greenbrook vs Heading Health Heading Health View all alternatives

FAQ About Greenbrook

Greenbrook is a leading provider of TMS therapy & Spravato® nasal esketamine treatment for depression & OCD.
Greenbrook was founded in 2011.
Greenbrook is headquartered in Mclean, United States.
Greenbrook operates in Health Care. Its work centres on TMS Therapy, Mental Health Care, Depression Treatment and Neurological Disorders.
Greenbrook has approximately 357 employees.
Greenbrook has completed 9 funding rounds, raising a total of $24.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Greenbrook include Neuronetics, Inc., Neuro Wellness Spa, Modalis TMS, Salience TMS Neuro Solutions, LLC, Cedar Psychiatry by Numinus. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Greenbrook and Neuronetics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Greenbrook, https://bouncewatch.com/company/greenbrook, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout